Phase III
The National Institute of Allergy & Infectious Diseases (NIAID) has founded a new clinical trials network focused on enrolling volunteers in clinical trials for COVID-19 vaccines and monoclonal antibodies.
Evive Biotech announced today that its Phase III study investigating F-627 to treat chemotherapy-induced neutropenia (CIN) in breast cancer patients has met its primary and secondary endpoints.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.
Immunomedics announced today that its Phase III study involving Trodelvy met its primary endpoint of progress-free survival, as well as secondary endpoints, in patients with metastatic triple-negative breast cancer who have previously received at least two prior therapies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 6, 2020.
Regeneron Pharmaceuticals, with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), is launching Phase III trials of REGN-COV2, the company’s two-antibody cocktail for the treatment and prevention of COVID-19.
ObsEva, based in Geneva, Switzerland and Boston, Massachusetts, announced topline data from the PRIMROSE 1 and 2 Phase III trials of Yselty (linzagolix) for uterine fibroids.
It’s not clear how long the trial will be delayed, but according to a report by STAT, it may still begin in July.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 3, 2020.
Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look.
PRESS RELEASES